Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase II trial (Alliance A171901)

Clicks: 1
ID: 314614
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #318 of 333 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Older adults remain underrepresented in prospective trials of immunotherapy for advanced lung cancer. To estimate pembrolizumab adverse events (AE), we conducted a multicenter, nonrandomized open-label phase II trial of oncologist-choice first-line pembrolizumab ± chemotherapy for older adults with advanced lung adenocarcinoma. METHODS: Alliance A171901 enrolled patients aged ≥70 years with stage IV or recurrent lung adenocarcinoma starting oncologist-choice of first-line pembrolizumab ± carboplatin and pemetrexed. The primary endpoint was the proportion of patients experiencing a solicited grade ≥3 AE within six months. Secondary endpoints included overall survival (OS), quality of life (QOL), and association of a geriatric assessment toxicity risk score with severe AEs. RESULTS: Among 95 evaluable patients, 43 (45.2%) received pembrolizumab and 52 (54.7%) received pembrolizumab plus chemotherapy. Median age was 77 years; 11.6% had an Eastern Cooperative Oncology Group performance status ≥2. During six months of treatment, 25.6% (95% CI 13.5 to 41.2%) experienced a solicited grade ≥3 AE in the monotherapy group and 42.3% (95% CI 28.7 to 56.8%) in the combination group. Median OS was 16.4 months (95% CI 10.1-not estimable) with monotherapy and 29.9 months (95% CI 16.4-not estimable) with combination therapy. QOL worsened during treatment. The geriatric assessment toxicity risk score was not associated with severe AEs with pembrolizumab ± chemotherapy. CONCLUSIONS: Older adults with advanced lung adenocarcinoma receiving pembrolizumab ± chemotherapy had comparable AE rates to those in prior registration trials that excluded frail patients. These findings can inform shared decision making and support inclusion of older adults in future trials. CLINICAL TRIAL: NCT04533451.
Reference Key
openalex_W7161980903 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Melisa L. Wong, Minji K. Lee, Oudom Kour, Daniel Satele, Carolyn J. Presley, Jennifer Le-Rademacher, Michael Ojelabi, Selina Chow, Thomas E Stinchcombe, Sherri Homan, Heidi D. Finnes, Saiama Waqar, Aminah Jatoi
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag157
URL
https://doi.org/10.1093/jnci/djag157
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.